The inventors have produced two high specificity and high affinity monoclonal antibodies that bind to human neuromedin U (NMU). Methods and compositions are provided for treating an individual in need thereof (e.g., an individual who is obese and/or has diabetes) by administering an anti-NMU/NMUR agent (e.g., an anti-NMU antibody). For example, methods and compositions are provided for increasing circulating insulin in an individual. Methods and compositions are also provided for detecting neuromedin U (NMU) (e.g., in a biological sample such as serum). Methods and compositions are also provided for predicting whether an individual will develop diabetes and/or PDAC, and for identifying an individual who would benefit from administration of an anti-NMU/NMUR agent.

A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.

A method for determining a presence of inflammatory bowel disease in a subject. The method involves providing a gut sample obtained from a subject; measuring a level in said gut sample of one or more proteins, wherein said one or more proteins comprises at least one of: leukotriene A-4 hydrolase, catalase, transketolase, thioredoxin domain containing protein 17, vasodilator-stimulated phosphoprotein and thymosin beta-10; and comparing said measured level of each of said one or more proteins to a corresponding protein level for a normal subject. A method for determining a presence of pancolitis in a subject with ulcerative colitis is also provided.

Disclosed is a method that uses Rho GDP dissociation inhibitory 2 protein as a diagnostic and prognostic marker of inflammatory bowel diseases by way of the ex vivo detection of the protein level in faecal samples of patients.

The present disclosure provides a novel method for treating pancreatic cancer and pancreatitis. The disclosure pertains to antagonists of dopamine receptors, that when combined with a glycolysis inhibitor, and a cholesterol lowering agent inhibit the growth of pancreatic cells.

Disclosed are methods, systems, and apparatuses for non-invasive detection of colitis in a subject. The methods involve depositing a bodily fluid sample from the subject on an internal reflection element (IRE). A beam of infrared (IR) radiation can then be directed through the IRE under conditions such that the IR radiation interacts with the bodily fluid sample. An absorption spectrum can then be recorded over a range of preselected frequencies to detect peaks that are affected by colitis. In preferred embodiments, the methods and systems involve Fourier Transform Infrared Spectroscopy (FTIR).

A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.

A hybridoma cell line NM002-1 secreting an anti-human pancreatic cancer monoclonal antibody and deposited under CCTCC Accession NO: C201173. Also, an anti-human pancreatic cancer monoclonal antibody NJ002-1 secreted by the hybridoma cell line NM002-1 and use thereof.